Skip to main content

Table 1 Expression of LL-37 transcript in monocyte-derived macrophages from healthy adults before and after supplementation

From: Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

  

LL-37 transcript (copy no.)

Day-0

Day-4

Day-8

Group-I

MDM

9.68 ± 9.0

64.37 ± 19.03a 1,2

21.61 ± 18.71b

Group-II

MDM

16.24 ± 1.77

62.42 ± 19.56c 3,4

38.25 ± 15.65

Group-III

MDM

10.94 ± 2.01

10.40 ± 16.19

41.05 ± 52.30

Group-IV

MDM

8.71 ± 4.64

33.87 ± 16.76

13.42 ± 9.57

Group-V

MDM

10.13 ± 5.41

11.54 ± 12.90

8.74 ± 6.27

  1. Note: Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d.. Data expressed as Mean ± Standard Deviation. One Way Analysis of Variance (ANOVA) method was used for statistical analysis. Differences are significant, when p < 0.05. Difference between, aday-4 and day-0 within Group-I (p = 0.01); bday-8 and day-0 within Group-I (p = 0.04); cday-4 and day-0 within Group-II (p = 0.01); 1Group-I and -III within day-4 (p = 0.02); 2Group-I and -V within day-4 (p = 0.034); 3Group-II and -III within day-4 (p = 0.031); 4Group-II and -V within day-4 (p = 0.035). PB, Phenylbutyrate; MDM, Monocyte-derived macrophages; b.d., Twice daily; o.d., Once daily.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us